Opinion

Published within

« | ... | 1560 | 1561 | 1562 | 1563 | 1564 | 1565 | 1566 | 1567 | 1568 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Bloomsbury: magical money pays for expansion

Published By Datamonitor
28 Jun 2001
Expert View
Expert View

Blood sugar management market abounds with opportunity

Humans are hard-wired to love sugar, courtesy of ancient relatives that were never quite sure where their next meal might come from. Consumption of foods high in energy-rich fat and sugar could mean the difference between life and death. That is not the case for modern-day consumers, but we still carry those same cravings for sugar that our caveman ancestors had.

Published By Datamonitor
20 May 2014
Expert View
Expert View

Blocking payments won't stop piracy

The nature of online piracy and emerging digital payment methods means that restricting payment options is likely to have only a limited impact. For payment companies this risks alienating some consumers and pushing them towards potentially untraceable alternatives; however, the risk of bad PR means providers may have little choice.

Published By Datamonitor
22 Feb 2013
CommentWire
CommentWire

Blockbuster: DVD giant beats predictable retreat from Europe

Blockbuster, the struggling US DVD retailer, is said to be looking for ways to pull out of Europe. Tough market conditions have forced Blockbuster to reconsider its presence in peripheral markets and focus on its core market at home in an attempt to turn the business around.

Published By Datamonitor
26 Jun 2006
ResearchWire
ResearchWire

Blockbuster patents: Merck & Co better protected

Published By Datamonitor
10 Mar 2005
Expert View
Expert View

Blockbuster marketing II Lipitor

Published By Datamonitor
24 Nov 2000
Expert View
Expert View

Blockbuster marketing I Vanlev

Published By Datamonitor
17 Nov 2000
Expert View
Expert View

Blockbuster brands generate generic goals

Despite being the current gold standard and sales heavyweight of the antipsychotic market with $4 billion in global sales, Eli Lilly's Zyprexa (olanzapine) is facing legal action in the US over alleged side effects. Along with other blockbuster drugs in the market, it may also run into intense competition from generics earlier than expected, according to new research from Datamonitor.

Published By Datamonitor
11 Feb 2005
CommentWire
CommentWire

Block exemption: reform in the slow lane

When amendments were made to the automotive industry's 'block exemption' legislation last year, many predicted significant change in the way cars were sold and serviced. With the compliance deadline looming however, signs of progress are few and far between.

Published By Datamonitor
29 Sep 2003
CommentWire
CommentWire

Block exemption: only Monti knows

The European Commission seems to be caving in to the growing pressure and lobbying from car manufacturers, by watering down some of its key proposals to inject more competition into the European car market. The news will be greeted with a sigh of relief from the industry, but no one is quite clear about the full extent of the changes.

Published By Datamonitor
17 Jul 2002

« | ... | 1560 | 1561 | 1562 | 1563 | 1564 | 1565 | 1566 | 1567 | 1568 | ... | » »|

No help is available.